# Phase 1/2 melanoma trials recruiting: 84 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 84 trials in phase 1/2 for melanoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 melanoma trials: 84 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/melanoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 84
- Recruiting or not yet: 84
- Read on: November 19, 2026

## Trials

The 25 newest of 84, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| September 25, 2026 | NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Melanoma, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841925) |
| September 14, 2026 | NCT07817901 | Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With... | Yonsei University | Phase 1/2 | Not yet recruiting | Unresectable or Metastatic Melanoma | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817901) |
| August 6, 2026 | NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Strand Therapeutics Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751042) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 5, 2026 | NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma | ReBio Pharma | Phase 1/2 | Not yet recruiting | Uveal Melanoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747935) |
| July 21, 2026 | NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC | Institute of Cancer Research, United Kingdom | Phase 1/2 | Recruiting | Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718243) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| June 4, 2026 | NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Beijing Biotech | Phase 1/2 | Recruiting | Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627698) |
| May 29, 2026 | NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma | Amsterdam UMC, location VUmc | Phase 1/2 | Not yet recruiting | Melanoma (Skin Cancer) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615881) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| January 28, 2026 | NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | Beijing Tide Pharmaceutical Co., Ltd | Phase 1/2 | Recruiting | Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer, Malignant... | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371663) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| January 14, 2026 | NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors | Onchilles Pharma Inc | Phase 1/2 | Recruiting | Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck... | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339176) |
| December 17, 2025 | NCT07288112 | DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma | Diakonos Oncology Corporation | Phase 1/2 | Recruiting | Refractory Melanoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288112) |
| December 17, 2025 | NCT07287917 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Aminex Therapeutics, Inc. | Phase 1/2 | Recruiting | Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287917) |
| December 15, 2025 | NCT07281924 | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis | University of Wisconsin, Madison | Phase 1/2 | Recruiting | Metastatic Melanoma, Liver Metastases | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281924) |
| December 12, 2025 | NCT07280832 | Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Shanghai JMT-Bio Inc. | Phase 1/2 | Recruiting | Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07280832) |
| August 22, 2025 | NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma | Novelwise Pharmaceutical Corporation | Phase 1/2 | Recruiting | Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136181) |
| August 11, 2025 | NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | AstraZeneca | Phase 1/2 | Recruiting | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115043) |
| July 17, 2025 | NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | GV20 Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070518) |
| July 17, 2025 | NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor | 1,438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070232) |
| July 14, 2025 | NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression | St Vincent's Hospital, Sydney | Phase 1/2 | Recruiting | Uveal Melanoma, Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07063875) |
| June 27, 2025 | NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 | Oncodesign Precision Medicine | Phase 1/2 | Not yet recruiting | Advanced Melanoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07040436) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Hadassah Medical Organization | 3 |
| Essen Biotech | 2 |
| The Netherlands Cancer Institute | 2 |
| Iovance Biotherapeutics, Inc. | 2 |
| National Cancer Institute (NCI) | 2 |
| GV20 Therapeutics | 2 |
| Strand Therapeutics Inc. | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Onchilles Pharma Inc | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Hummingbird Bioscience | 1 |
| Obsidian Therapeutics, Inc. | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| Shenzhen Geno-Immune Medical Institute | 1 |
| IDEAYA Biosciences | 1 |
| Arvinas Inc. | 1 |
| University of Utah | 1 |
| Binhui Biopharmaceutical Co., Ltd. | 1 |
| Aminex Therapeutics, Inc. | 1 |
| Neonc Technologies, Inc. | 1 |
| ReBio Pharma | 1 |
| M.D. Anderson Cancer Center | 1 |
| CJ Bioscience, Inc. | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| VM Discovery, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 51 |
| Australia | 16 |
| China | 15 |
| South Korea | 6 |
| United Kingdom | 5 |
| Germany | 5 |
| Netherlands | 5 |
| Israel | 5 |
| Spain | 5 |
| Japan | 4 |
| Italy | 4 |
| France | 3 |
| Sweden | 3 |
| Canada | 3 |
| Taiwan | 3 |
| Brazil | 2 |
| Portugal | 2 |
| Belgium | 2 |
| Turkey (Türkiye) | 2 |
| Singapore | 1 |
| Denmark | 1 |
| Hungary | 1 |
| Russia | 1 |
| Ukraine | 1 |
| Argentina | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Endodontics practices in the United States](https://specstream.ai/data/businesses/endodontics-practices/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Dental hygiene clinics in the United States](https://specstream.ai/data/businesses/dental-hygiene-clinics/united-states)
